# Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

> **NCT01403415** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Childhood B Acute Lymphoblastic Leukemia
- Childhood T Acute Lymphoblastic Leukemia
- Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Methotrexate
- **DRUG:** Mitoxantrone Hydrochloride
- **DRUG:** Pegaspargase
- **OTHER:** Pharmacological Study
- **DRUG:** Temsirolimus
- **DRUG:** Vincristine Sulfate

## Key facts

- **NCT ID:** NCT01403415
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2015-05
- **Final completion:** —
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01403415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01403415, "Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01403415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*